Aligos Therapeutics, Inc. – NASDAQ:ALGS
Aligos Therapeutics stock price today
$8.75
-32.4
-78.74%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Aligos Therapeutics stock price monthly change
+7814.98%
month
Aligos Therapeutics stock price quarterly change
+7814.98%
quarter
Aligos Therapeutics stock price yearly change
+5472.86%
year
Aligos Therapeutics key metrics
Market Cap | 138.46M |
Enterprise value | N/A |
P/E | -0.39 |
EV/Sales | -2.17 |
EV/EBITDA | 0.33 |
Price/Sales | 2.77 |
Price/Book | 0.37 |
PEG ratio | -0.01 |
EPS | -1.43 |
Revenue | 13.79M |
EBITDA | -84.03M |
Income | -99.58M |
Revenue Q/Q | -63.78% |
Revenue Y/Y | -1.89% |
Profit margin | -690.63% |
Oper. margin | -701.66% |
Gross margin | 0% |
EBIT margin | -701.66% |
EBITDA margin | -609.27% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAligos Therapeutics stock price history
Aligos Therapeutics stock forecast
Aligos Therapeutics financial statements
| Jun 2023 | 6.88M | -18.79M | -272.89% |
|---|---|---|---|
| Sep 2023 | 3.23M | -18.04M | -556.99% |
| Dec 2023 | 2.68M | -27.89M | -1040.36% |
| Mar 2024 | 986K | -34.86M | -3535.8% |
| Mar 2024 | 986K | -34.86M | -3535.8% |
|---|---|---|---|
| Sep 2025 | 4.12M | -31.68M | -768.06% |
| Oct 2025 | 1.42M | -28.10M | -1970.39% |
| Dec 2025 | 1.51M | -26.54M | -1749.83% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 106130000 | 36.49M | 34.39% |
|---|---|---|---|
| Sep 2023 | 85852000 | 31.03M | 36.14% |
| Dec 2023 | 153903000 | 61.82M | 40.17% |
| Mar 2024 | 127902000 | 68.10M | 53.25% |
| Jun 2023 | -13.61M | 25.00M | 414K |
|---|---|---|---|
| Sep 2023 | -20.33M | -9K | -21K |
| Dec 2023 | -22.65M | -7K | 87.93M |
| Mar 2024 | -22.74M | -88.64M | -19K |
Aligos Therapeutics alternative data
| Aug 2023 | 69 |
|---|---|
| Sep 2023 | 68 |
| Oct 2023 | 68 |
| Nov 2023 | 68 |
| Dec 2023 | 68 |
| Jan 2024 | 68 |
| Feb 2024 | 68 |
| Mar 2024 | 66 |
| Apr 2024 | 66 |
| May 2024 | 66 |
| Jun 2024 | 67 |
| Jul 2024 | 67 |
Aligos Therapeutics other data
21.42%
-40.55%
of ALGS is owned by hedge funds
19
-19
9.16M
-17.34M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2023 | 11900401 | 0 |
| Patent |
|---|
Application Filling date: 15 Feb 2022 Issue date: 9 Jun 2022 |
Application Filling date: 22 Nov 2021 Issue date: 2 Jun 2022 |
Application CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING Filling date: 18 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 5 Nov 2021 Issue date: 12 May 2022 |
Application Filling date: 5 Nov 2021 Issue date: 12 May 2022 |
Application Filling date: 5 Nov 2021 Issue date: 12 May 2022 |
Application Filling date: 26 Oct 2021 Issue date: 28 Apr 2022 |
Application Filling date: 19 Oct 2021 Issue date: 21 Apr 2022 |
Application Filling date: 13 Oct 2021 Issue date: 21 Apr 2022 |
Application Filling date: 30 Mar 2021 Issue date: 14 Apr 2022 |
| Insider | Compensation |
|---|---|
Dr. Lawrence M. Blatt MBA, Ph.D. (1962) Chief Executive Officer & Chairman | $900,080 |
| Dr. Leonid Beigelman Ph.D. (1958) Pres & Director | $690,830 |
Dr. Julian A. Symons DPHIL (1961) Executive Vice President & Chief Scientific Officer | $580,110 |
-
What's the price of Aligos Therapeutics stock today?
One share of Aligos Therapeutics stock can currently be purchased for approximately $8.75.
-
When is Aligos Therapeutics's next earnings date?
Unfortunately, Aligos Therapeutics's (ALGS) next earnings date is currently unknown.
-
Does Aligos Therapeutics pay dividends?
No, Aligos Therapeutics does not pay dividends.
-
How much money does Aligos Therapeutics make?
Aligos Therapeutics has a market capitalization of 138.46M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.66% to 15.53M US dollars.
-
What is Aligos Therapeutics's stock symbol?
Aligos Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ALGS".
-
What is Aligos Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aligos Therapeutics?
Shares of Aligos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aligos Therapeutics's key executives?
Aligos Therapeutics's management team includes the following people:
- Dr. Lawrence M. Blatt MBA, Ph.D. Chief Executive Officer & Chairman(age: 63, pay: $900,080)
- Dr. Leonid Beigelman Ph.D. Pres & Director(age: 67, pay: $690,830)
- Dr. Julian A. Symons DPHIL Executive Vice President & Chief Scientific Officer(age: 64, pay: $580,110)
-
How many employees does Aligos Therapeutics have?
As Jul 2024, Aligos Therapeutics employs 67 workers, which is 2% more then previous quarter.
-
When Aligos Therapeutics went public?
Aligos Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 16 Oct 2020.
-
What is Aligos Therapeutics's official website?
The official website for Aligos Therapeutics is aligos.com.
-
Where are Aligos Therapeutics's headquarters?
Aligos Therapeutics is headquartered at One Corporate Drive, South San Francisco, CA.
-
How can i contact Aligos Therapeutics?
Aligos Therapeutics's mailing address is One Corporate Drive, South San Francisco, CA and company can be reached via phone at +800 4666059.
Aligos Therapeutics company profile:
Aligos Therapeutics, Inc.
aligos.comExchange:
NASDAQ
Full time employees:
68
Industry:
Biotechnology
Sector:
Healthcare
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-Ăź agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
One Corporate Drive
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001799448
ISIN: US01626L1052
CUSIP: 01626L105
